Atsilok - Instructions For Use, Indications, Doses

Table of contents:

Atsilok - Instructions For Use, Indications, Doses
Atsilok - Instructions For Use, Indications, Doses

Video: Atsilok - Instructions For Use, Indications, Doses

Video: Atsilok - Instructions For Use, Indications, Doses
Video: How to Use a Metered Dose Inhaler 2024, November
Anonim

Atsilok

Instructions for use:

  1. 1. Release form and composition
  2. 2. Indications for use
  3. 3. Contraindications
  4. 4. Method of application and dosage
  5. 5. Side effects
  6. 6. Special instructions
  7. 7. Drug interactions
  8. 8. Terms and conditions of storage

Prices in online pharmacies:

from 212 rub.

Buy

Solution for intravenous and intramuscular administration of Atsilok
Solution for intravenous and intramuscular administration of Atsilok

Atsilok is an antiulcer drug, a blocker of H 2 -histamine receptors.

Release form and composition

Dosage forms:

  • coated tablets: biconvex, 150 mg - round, 300 mg - capsule-shaped, film shell - green (10 pieces in aluminum strips, in a cardboard box 2 or 10 strips);
  • solution for intravenous (i / v) and intramuscular (i / m) administration: clear liquid from pale yellow to colorless (2 ml in ampoules, in a blister 5 ampoules, in a cardboard box 1 blister).

1 tablet contains:

  • active substance: ranitidine (in the form of hydrochloride) - 150 mg or 300 mg;
  • auxiliary components: calcium stearate, calcium hydrogen phosphate granular, sodium carboxymethyl starch, sodium hydrogen phosphate, microcrystalline cellulose, colloidal silicon dioxide (aerosil), croscarmellose sodium, Opadrai green dye.

1 ml of solution contains:

  • active substance: ranitidine (in the form of hydrochloride) - 25 mg;
  • auxiliary components: phenol, sodium hydrogen phosphate dihydrate, potassium dihydrogen phosphate, water for injection.

Indications for use

Film-coated tablets

  • ulcer of the stomach and duodenum, which arose while taking non-steroidal anti-inflammatory drugs (NSAIDs);
  • prevention of exacerbations and treatment of stomach and duodenal ulcers;
  • prevention of recurrence of bleeding from the upper gastrointestinal tract (GIT);
  • Zollinger-Ellison syndrome;
  • erosive esophagitis, reflux esophagitis;
  • prevention of aspiration of gastric juice during operations under general anesthesia (Mendelssohn's syndrome);
  • prevention and treatment of ulcers of the upper gastrointestinal tract, which have arisen after surgery or stress.

Solution for i / v and i / m administration

  • prevention of recurrent bleeding in gastric ulcer and / or duodenal ulcer and bleeding in stress ulcers;
  • prevention of Mendelssohn's syndrome.

Contraindications

  • age up to 12 years;
  • the period of pregnancy and breastfeeding;
  • individual intolerance to the components of the drug.

It is recommended to prescribe Atsilok with caution to patients with renal and / or hepatic insufficiency, acute porphyria (including history), with cirrhosis of the liver with a history of portosystemic encephalopathy.

Method of administration and dosage

Film-coated tablets

The tablets are taken orally, swallowing whole, regardless of food intake, with a sufficient amount of liquid.

Recommended dosage regimen:

  • ulcers of the stomach and duodenum associated with the intake of NSAIDs: 150 mg 2 times a day (morning and evening) or 300 mg 1 time a day (at night). Duration of treatment is 8–12 weeks;
  • prevention of ulcer formation while taking NSAIDs: 150 mg 2 times a day;
  • ulcer of the stomach and duodenum: treatment - 150 mg 2 times a day or 300 mg 1 time a day. If necessary, administration of 300 mg 2 times a day is indicated. The course of treatment is 4–8 weeks. Prevention of exacerbations - 150 mg (for smoking patients - 300 mg) 1 time per day, at night;
  • prevention of recurrent bleeding: 150 mg 2 times a day;
  • ulcers after surgery or stress: 150 mg 2 times a day, the course of treatment is 4–8 weeks;
  • erosive reflux esophagitis: treatment - 150 mg in the morning and evening or 300 mg at night. In the absence of the desired therapeutic effect, a dose of 150 mg 4 times a day is indicated. The course of treatment is 8-12 weeks. Prevention - 150 mg 2 times a day for a long period;
  • Zollinger-Ellison syndrome: the initial dose is 150 mg 3 times a day, if necessary, the dose can be increased. Reception is continued as needed;
  • prevention of Mendelssohn's syndrome: in the evening, on the eve of the operation - 150 mg and 2 hours before the start of general anesthesia - 150 mg.

With impaired liver function, dose reduction is possible.

In renal failure with creatinine clearance (CC) less than 50 ml / min, the daily dose should not exceed 150 mg.

Solution for i / v and i / m administration

Acylok in the form of a solution is used for intravenous and intramuscular administration.

Parenterally, the drug is prescribed to patients who are temporarily unable to take it in pill form, then transferred to oral therapy.

The recommended dosage for the prevention of recurrent bleeding in gastric ulcer and / or duodenal ulcer and bleeding in stress ulcers:

  • IM injection: 50 mg every 6-8 hours;
  • IV injection: 50 mg (2 ml) diluted in 0.9% sodium chloride solution or dextrose solution for injection to a total volume of 20 ml. The dose is administered slowly (within 5 minutes) at intervals of 6-8 hours.

To prevent the development of Mendelssohn's syndrome, the patient is injected 1 hour before general anesthesia intramuscularly or intravenously 50 mg of the drug.

In renal failure (CC less than 50 ml / min), a single dose should not exceed 25 mg.

Side effects

  • cardiovascular system: bradycardia, arrhythmia, decreased blood pressure (BP), atrioventricular block; against the background of parenteral administration - asystole;
  • digestive system: dry mouth, nausea, vomiting, diarrhea, abdominal pain, constipation, increased activity of liver enzymes, acute pancreatitis, hepatitis (cholestatic, hepatocellular, mixed);
  • endocrine system: gynecomastia, amenorrhea, hyperprolactinemia, impotence, decreased libido;
  • hematopoietic organs: thrombocytopenia, leukopenia, pancytopenia, agranulocytosis, immune hemolytic anemia, aplasia and hypoplasia of the bone marrow;
  • sense organs: paresis of accommodation, blurred visual perception;
  • nervous system: drowsiness, tinnitus, fatigue, headache, confusion, dizziness, irritability, hallucinations (more often in severely ill or elderly patients), involuntary movements;
  • musculoskeletal system: myalgia, arthralgia;
  • allergic reactions: skin rash, urticaria, bronchospasm, angioedema, exudative erythema multiforme, anaphylactic shock;
  • others: acute porphyria, alopecia, increased activity of glutamate transpeptidase, hypercreatininemia.

special instructions

The appointment of Atsilok should be made only after excluding the presence of an ulcer cancer in the patient, since the use of ranitidine can hide the symptoms of gastric carcinoma.

The effectiveness of ranitidine decreases in tobacco-dependent patients.

Cancellation of the drug must be made by gradually reducing the daily dose.

Prolonged therapy of debilitated patients under stress can cause gastric damage of bacterial etiology with the risk of spreading the infection.

Ranitidine can cause false positives when tested for protein in urine.

In order to prevent a significant decrease in the absorption of ketoconazole or itraconazole, Acylok is recommended to be used 2 hours after taking them.

Blockers of H 2 -histaminoreceptors can interfere with the action of histamine and pentagastrin on the acid-forming function of the stomach, therefore, it is not recommended to use the drug within 24 hours before the test.

Since ranitidine can suppress the skin reaction to histamine and lead to false positive results, it is recommended that it be discontinued before performing diagnostic skin tests.

During the period of treatment, the patient should refrain from driving vehicles and mechanisms.

Drug interactions

While taking Atsilok:

  • metoprolol - increases the half-life, increasing its concentration in serum by 50%;
  • itraconazole and ketoconazole - reduce absorption;
  • antacids, sucralfate in high doses - can slow down the absorption of ranitidine (it is recommended to observe an interval of at least two hours between taking these drugs);
  • bone marrow depressants - increase the risk of developing neutropenia.

Ranitidine inhibits the metabolism in the liver of aminophenazone, phenazone, diazepam, hexobarbital, diazepam, lidocaine, propranolol, phenytoin, theophylline, indirect anticoagulants, glipizide, aminophylline, buformin, calcium antagonists, metronidazole.

Terms and conditions of storage

Keep out of the reach of children. Store in a dark place at temperatures up to 25 ° C, do not freeze the solution.

Shelf life: tablets - 3 years, solution - 2 years.

Atsilok: prices in online pharmacies

Drug name

Price

Pharmacy

Acylok 25 mg / ml solution for intravenous and intramuscular administration 2 ml 10 pcs.

212 r

Buy

Atsilok solution for intravenous and intramuscular injection. 2.5% 2ml 10 pcs.

224 r

Buy

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!

Recommended: